GlassScriptPhysician profile
Anthony J Desmarais
NPI 1073048138
$2,951.49
in general payments reported to CMS, 2019-2025
29 companies · $528 in 2025
The $528 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.39 · 2020: $637 · 2021: $915 · 2022: $219 · 2023: $128 · 2024: $493 · 2025: $528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,149.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $382.57 | 2019-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $261.81 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $252.47 | 2021-2025 | Ozempic |
| Glaxosmithkline, LLC. | $249.83 | 2020-2023 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $213.34 | 2020-2024 | Farxiga |
| Novartis Pharmaceuticals Corporation | $173.51 | 2020-2025 | |
| Abbvie INC. | $165.60 | 2020-2024 | Ubrelvy |
| Boston Scientific Corporation | $123.66 | 2024-2025 | Watchman Flx, General - Pain Management |
| Pfizer INC. | $122.03 | 2020-2024 | |
| Astellas Pharma US INC | $112.58 | 2020-2021 | |
| Amarin Pharma, INC. | $108.24 | 2020-2021 | |
| Renalytix Ai, INC. | $106.26 | 2024-2025 | Kidneyintelx Blood Collection Convenience Kit |
| Sanofi-Aventis U.S. LLC | $99.65 | 2020 | |
| Exact Sciences Corporation | $90.93 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Esperion Therapeutics, INC. | $59.78 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $53.50 | 2021 | |
| Radius Health, INC. | $49.47 | 2020 | |
| Philips North America LLC | $47.46 | 2020-2025 | Extended Holter |
| Janssen Pharmaceuticals, INC | $41.40 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $33.49 | 2020-2021 | |
| Nestle Healthcare Nutrition INC. | $32.56 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.58 | 2020 | |
| Dexcom, INC. | $29.35 | 2024 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $27.24 | 2025 | Gemtesa |
| Arbor Pharmaceuticals, INC. | $24.48 | 2020-2021 | |
| Ibsa Pharma INC. | $19.91 | 2020 | |
| Nabriva Therapeutics, Plc | $15.49 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.19 | 2020 | |
| Biosense Webster, INC. | $12.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Desmarais listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.